SPK-FIX: Phase I/II data

Top-line data from the first 3 severe hemophilia B patients in an open-label, dose-escalation, U.S. Phase I/II trial showed that a single dose of 5x10^11 vg/kg IV SPK-9001

Read the full 285 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE